Autres langues HK inno.N Corporation

Actions

A195940

KR7195940002

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
38 750 ^KRW	-1,27 %		+2,51 %	-12,82 %

2022	Sebela Pharmaceuticals® acquiert les droits de licence exclusifs de HK inno.N Corporation pour développer et commercialiser le tégoprazan aux États-Unis et au Canada	CI
2022	Sebela Pharmaceuticals conclut un partenariat exclusif avec HK inno.N Corporation	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	28/10/22
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	19/10/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	09/08/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	09/08/22
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.	09/08/22
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%	11/05/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	11/05/22
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets	11/05/22
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation	11/05/22
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China	18/04/22
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors	24/02/22
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.	09/02/22
HK inno.N Corporation authorizes a Buyback Plan.	09/02/22
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio	30/12/21
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	28/12/21
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US	27/12/21
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index	20/12/21
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.	03/08/21
HK inno.N Corporation has filed an IPO.	04/05/21
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.	22/04/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HK inno.N Corporation

Actions

A195940

KR7195940002

Autres langues

Filtres